Annual report pursuant to Section 13 and 15(d)

Discontinuing Operations - Summarized results of consolidated discontinued operations (Details)

v3.21.1
Discontinuing Operations - Summarized results of consolidated discontinued operations (Details) - USD ($)
$ in Thousands
12 Months Ended
Oct. 24, 2019
Jul. 15, 2019
Jul. 08, 2019
Dec. 31, 2020
Dec. 31, 2019
Income Statement Disclosures          
Gain (loss) on disposal of business         $ (8,370)
Net income from discontinuing operations       $ 42 177
Current assets of discontinuing operations:          
Current assets of discontinuing operations       0 71
Current liabilities of discontinuing operations          
Current liabilities of discontinuing operations       659 1,229
Cash Flow Disclosures          
Income from discontinuing operations       42 177
Adjustments to reconcile income from discontinuing operations to net cash used in operating activities, discontinuing operations          
Gain (loss) on disposal of business         (8,370)
Change in working capital components:          
Net cash used in operating activities, discontinuing operations       (463) (5,421)
Discontinuing Operations          
Income Statement Disclosures          
Revenue       0 10,066
Cost of revenues       0 7,554
Gross profit       0 2,512
Research and development       0 937
General and administrative       (42) 4,675
Sales and marketing       0 1,527
Restructuring costs       0 194
Transaction costs       0 560
Impairment of patents and other intangible assets       0 601
Total operating expenses       (42) 8,494
Income (loss) from discontinuing operations       42 (5,982)
Interest expense       0 (2,211)
Total other income       0 6,159
Net income from discontinuing operations       42 177
Current assets of discontinuing operations:          
Accounts receivable, net of allowance for doubtful accounts of $4,536 in 2019       0 71
Allowance for doubtful accounts         4,536
Current assets of discontinuing operations       0 71
Current liabilities of discontinuing operations          
Accounts payable and accrued expenses       659 1,137
Due to Interpace Biosciences, Inc.       0 92
Current liabilities of discontinuing operations       659 1,229
Cash Flow Disclosures          
Income from discontinuing operations       42 177
Adjustments to reconcile income from discontinuing operations to net cash used in operating activities, discontinuing operations          
Depreciation       0 542
Amortization       0 613
Provision for bad debts       (28) 1,074
Accounts payable settlements       (43) 0
Stock-based compensation       (6) 107
Amortization of operating lease right-of-use assets       0 358
Amortization of discount of debt and debt issuance costs       0 601
Interest added to Convertible Note       0 343
Loss on extinguishment of debt       0 328
Change in working capital components:          
Accounts receivable       99 845
Other current assets       0 398
Other non-current assets       0 2
Accounts payable, accrued expenses and deferred revenue       (435) (2,163)
Obligations under operating leases       0 (217)
Deferred rent payable and other       0 (151)
Due to Interpace Biosciences, Inc.       (92) 92
Net cash used in operating activities, discontinuing operations       (463) (5,421)
Clinical Business Disposal | Discontinuing Operations          
Income Statement Disclosures          
Gain (loss) on disposal of business     $ (1,222) 0 (1,222)
Adjustments to reconcile income from discontinuing operations to net cash used in operating activities, discontinuing operations          
Gain (loss) on disposal of business     $ (1,222) 0 (1,222)
BioPharma Disposal          
Income Statement Disclosures          
Interest expense $ (24)        
BioPharma Disposal | Discontinuing Operations          
Income Statement Disclosures          
Gain (loss) on disposal of business   $ (7,148)   0 (7,148)
Current assets of discontinuing operations:          
Accounts receivable, net of allowance for doubtful accounts of $4,536 in 2019   4,271      
Adjustments to reconcile income from discontinuing operations to net cash used in operating activities, discontinuing operations          
Gain (loss) on disposal of business   $ (7,148)   $ 0 $ (7,148)